Supplementary Material for: International Reporting Scale of <i>BCR-ABL1</i> Fusion Transcript in Chronic Myeloid Leukemia: First Report from India
Balasubramanian P.
Chendamarai E.
Markose P.
Fletcher L.
Branford S.
George B.
Mathews V.
Chandy M.
Srivastava A.
10.6084/m9.figshare.5123104.v1
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_International_Reporting_Scale_of_i_BCR-ABL1_i_Fusion_Transcript_in_Chronic_Myeloid_Leukemia_First_Report_from_India/5123104
Achieving a major molecular response (MMR) is an important predictor of progression-free survival in chronic myeloid leukemia patients treated with imatinib. This requires accurate measurement of <i>BCR-ABL1</i> transcripts normalized to a control gene, as well as defining a level (<i>BCR-ABL1</i>/control gene ratio) that will correlate with sustained clinical response. To make these measurements comparable between laboratories, an international scale (IS) is necessary. A <i>BCR-ABL1</i>/control gene ratio of 0.10% represents MMR in the IS. In collaboration with an international reference laboratory in Adelaide, S.A., Australia, we have established and validated a lab-specific conversion factor for expressing <i>BCR-ABL1</i> transcript levels in the IS. In this report, we explain the process and steps involved in obtaining a valid lab-specific conversion factor for expressing <i>BCR-ABL1</i> transcript levels in the IS.
2012-01-12 00:00:00
Chronic myeloid leukemia
Complete cytogenetic response
BCR-ABL1 transcripts
Major molecular response